Next Article in Journal
Micro- and Nanoplastics as Potential Drivers of Dilated Cardiomyopathy
Previous Article in Journal
Optimizing Timing and Dose of Starting Norepinephrine and Vasopressin in Septic Shock
Previous Article in Special Issue
Interactions Between the Gut Microbiome and Genetic and Clinical Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Patients with Type 2 Diabetes Mellitus from Different Geographical Regions of Argentina
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Life
Volume 16
Issue 6
10.3390/life16060915
life-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Editorial

Advances in Non-Alcoholic Fatty Liver Disease: Pathophysiology, Diagnosis, and Emerging Therapies

by
Ioannis Katsaros
* and
Dimitrios Schizas
First Department of Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece
*
Author to whom correspondence should be addressed.
Life 2026, 16(6), 915; https://doi.org/10.3390/life16060915
Submission received: 17 May 2026 / Accepted: 25 May 2026 / Published: 29 May 2026
(This article belongs to the Special Issue Advances in Non-Alcoholic Fatty Liver Disease: Pathophysiology, Diagnosis, and Emerging Therapies)
Versions Notes

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as one of the most pressing public health challenges, affecting more than 30% of the global adult population and projected to exceed 55% prevalence by 2040 [...]

Share and Cite

MDPI and ACS Style

Katsaros, I.; Schizas, D. Advances in Non-Alcoholic Fatty Liver Disease: Pathophysiology, Diagnosis, and Emerging Therapies. Life 2026, 16, 915. https://doi.org/10.3390/life16060915

AMA Style

Katsaros I, Schizas D. Advances in Non-Alcoholic Fatty Liver Disease: Pathophysiology, Diagnosis, and Emerging Therapies. Life. 2026; 16(6):915. https://doi.org/10.3390/life16060915

Chicago/Turabian Style

Katsaros, Ioannis, and Dimitrios Schizas. 2026. "Advances in Non-Alcoholic Fatty Liver Disease: Pathophysiology, Diagnosis, and Emerging Therapies" Life 16, no. 6: 915. https://doi.org/10.3390/life16060915

APA Style

Katsaros, I., & Schizas, D. (2026). Advances in Non-Alcoholic Fatty Liver Disease: Pathophysiology, Diagnosis, and Emerging Therapies. Life, 16(6), 915. https://doi.org/10.3390/life16060915

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop